Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease  by Wæhre, Torgun et al.
Coronary Artery Disease and Atherosclerosis
Hydroxymethylglutaryl Coenzyme A
Reductase Inhibitors Down-Regulate
Chemokines and Chemokine Receptors
in Patients With Coronary Artery Disease
Torgun Wæhre, MD,*† Jan K. Dama˚s, MD, PHD,*† Lars Gullestad, MD, PHD,§ Are M. Holm, MD,*
Terje R. Pedersen, MD, PHD, Kjell E. Arnesen, MD,¶ Harald Torsvik, MD, PHD,§
Stig S. Frøland, MD, PHD,*‡ Anne G. Semb, MD, PHD, Pa˚l Aukrust, MD, PHD*‡
Oslo, Bærum, and Lørenskog, Norway
OBJECTIVES We sought to investigate whether the activation of the chemokine network observed in
patients with coronary artery disease (CAD) could be modified by treatment with 3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors (statins).
BACKGROUND Chemokines and chemokine receptors are important mediators in atherogenesis, and we
hypothesized that the statins could affect the chemokine network in CAD.
METHODS Thirty CAD patients without previous statin therapy were randomized to receive atorvastatin
(80 mg/day, n  15) or simvastatin (20 mg/day, n 15). Peripheral blood mononuclear cells
(PBMCs) and plasma were obtained at baseline and after six months of statin therapy.
Messenger ribonucleic acid (mRNA) expression of chemokines and chemokine receptors in
PBMCs was analyzed by ribonuclease protection assay and real-time reverse-transcription
polymerase chain reaction. Chemokines were also examined in the supernatants from
unstimulated and lipopolysaccharide-stimulated PBMCs (and in plasma).
RESULTS Our main findings were: 1) gene expression of several chemokines (i.e., macrophage
inflammatory protein [MIP]-1, MIP-1, and interleukin [IL]-8) and chemokine receptors
(i.e., CC chemokine receptor [CCR]1, CCR2, CCR4, and CCR5) was markedly increased
among CAD patients compared with healthy control subjects; 2) treatment with atorvastatin
and simvastatin markedly reduced the mRNA levels of some of these chemokines (i.e.,
MIP-1, MIP-1, IL-8) and receptors (i.e., CCR1 and CCR2), with the most pronounced
effect in the atorvastatin group; and 3) statin therapy reduced the spontaneous release of IL-8
and MIP-1 from PBMCs in CAD patients.
CONCLUSIONS This study demonstrates a down-regulatory effect of statins on the chemokine network in
CAD patients, possibly contributing to the beneficial effects of statins in this
disorder. (J Am Coll Cardiol 2003;41:1460–7) © 2003 by the American College of
Cardiology Foundation
Atherosclerosis has elements of both lipid deposition and
inflammation. Hypercholesterolemia is an established risk
factor for atherosclerosis and coronary artery disease
(CAD), but these patients also have raised plasma levels of
inflammatory cytokines, enhanced activation of circulating
leukocytes, and extensive infiltration of blood-derived mac-
rophages and T cells into atherosclerotic plaques, reflecting
an important pathogenic role of inflammation in atherogen-
esis (1).
Several clinical trials of 3-hydroxy-3-methylglutaryl co-
enzyme A reductase inhibitors (statins) have demonstrated
improved prognosis of patients with CAD (2). This effect
was thought to be predominantly attributed to their lipid-
lowering properties, but recent studies suggest that other
properties of statins such as immunomodulatory effects may
also be beneficial in CAD (3). Accordingly, the reduction of
cardiovascular events observed during statin therapy appears
to be particularly prominent in patients with elevated
C-reactive protein, suggesting anti-inflammatory effects of
these agents (4).
Recruitment of leukocytes into the vascular wall is a
crucial feature of all stages of atherosclerosis. Increasing
evidence suggests that chemokines or chemotactic cytokines
play an important role in this process, not only by directing
leukocytes into the vessel wall but also by activating these
cells within the atherosclerotic lesion (5). Consequently, the
chemokine network could represent an important therapeu-
tic target in this disorder.
Although there are several reports of potential anti-
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inflammatory properties of statins, the knowledge of the
effect of these medications on chemokines and chemokine
receptors is scarce, mostly based on in vitro studies and
animal models (6–8). We hypothesized that the beneficial
effects of statins in CAD could be related to the effects on
the chemokine network. This hypothesis was investigated in
an open-label, randomized study analyzing the expression of
several CC and CXC chemokines and their receptors (CCR
and CXCR) in peripheral blood mononuclear cells
(PBMCs) isolated from CAD patients before and after six
months of therapy with “high-dose” atorvastatin or
“conventional-dose” simvastatin, representing two extremi-
ties of statin therapy.
METHODS
Patients. Thirty patients with a previous myocardial infarc-
tion and without statin therapy were included in the study.
Exclusion criteria were myocardial infarction within the last
six weeks, severe concomitant disease (e.g., infections,
connective tissue disease, malignancies), congestive heart
failure, and the use of medications other than aspirin with
known anti-inflammatory effects. None of the patients
experienced mild inflammatory or infectious disorders in the
last four weeks before blood sampling. Patients were ran-
domized to simvastatin 20 mg/day (n  15) or atorvastatin
80 mg/day (n  15) in an open fashion, and non-fasting
venous blood was collected at baseline and after six months
of therapy. The demographic and clinical characteristics of
the patients are shown in Table 1, demonstrating no
significant differences between the treatment groups. Fif-
teen healthy blood donors (age 50.1  6.4 years; 4 women
and 11 men) without any known cardiovascular disease
served as the control group. The regional ethical committee
approved the study. All patients gave their written, in-
formed consent.
Blood sampling protocol and isolation of cells.
Peripheral venous blood was drawn into pyrogen-free tubes
with ethylenediamide tetraacetic acid (EDTA) or heparin as
anticoagulants. For plasma, the EDTA tubes were placed
on melting ice, centrifuged within 15 min at 1,500 g for 10
min at 4°C. Plasma was stored at 80°C, and the samples
were thawed only once.
The PBMCs were obtained from heparinized blood by
Isopaque-Ficoll (Lymphoprep; Nycomed, Oslo, Norway)
gradient centrifugation. Cells were immediately stored in
liquid nitrogen as pellets or cryopreserved in 10% dimeth-
ylsulfoxide (Sigma, St. Louis, Missouri), 25% fetal calf
serum (Myoclone; Gibco, Paisley, U.K.), and 65% RPMI
1640 medium with 2 mmol/l L-glutamine and 25 mmol/l
HEPES buffer (Gibco), as previously described (9).
Ribonuclease protection assay. Total ribonucleic acid was
isolated from frozen PBMC pellets using the RNeasy
Minikit (Qiagen, Hilden, Germany), subjected to DNase I
treatment (RQI DNase; Promega, Madison, Wisconsin),
quantified spectrophotometrically, and stored at 80°C.
The ribonuclease protection assay was performed as previ-
ously described with chemokine (hCK5) and chemokine
receptor (hCR5) multiprobes from Pharmigen (San Diego,
California) (10).
Real-time quantitative reverse-transcription polymerase
chain reaction. Total ribonucleic acid was isolated from
PBMCs, as described earlier. Real-time SyBr Green or
Taq-Man quantitative reverse transcription-polymerase
chain reaction was performed using the ABI Prism 7700
(Applied Biosystems, Foster City, California), and
sequence-specific polymerase chain reaction primers and
probes for the actual genes were: CXCR1 (forward primer
[FP]: 5-CATCAAGTGCCCTCTAGCTGTTAA-3;
reverse primer [RP]: 5GCAATGGTTTGATCT-
AACTGAAGG-3), CXCR2 (FP: 5GCCTGTCT-
TACTTTTCCGAAGGA-3; RP: 5-CCGCCA-




GAGTCATAG-3). The house-keeping gene beta-actin
(Applied Biosystems) was included as an endogenous con-
trol. Standard curves were run on the same plates, and the
Abbreviations and Acronyms
CAD  coronary artery disease
CCR  CC chemokine receptor
CXCR  CXC chemokine receptor
IL  interleukin
MCP  monocyte chemoattractant protein
MIP  macrophage inflammatory protein
mRNA  messenger ribonucleic acid
PBMCs  peripheral blood mononuclear cells
RANTES  regulated upon activation, normally T cell
expressed and secreted







Age (yrs) 58.3  7.1 61.1  8.4
Gender (female/male) 5/10 2/13





Calcium antagonists 1/14 4/11
ACE inhibitors 4/11 3/12
Warfarin 3/12 7/8
Diabetes (/) 1/14 3/12
Hypertension (/) 3/12 7/8
Cerebral vascular disease (/) 4/11 1/14
Peripheral arterial disease (/) 2/13 1/14
Systolic blood pressure (mm Hg) 129  30 130  21
Diastolic blood pressure (mm Hg) 81  13 81  9
Data are presented as the mean value  SD, unless otherwise indicated. There were
no significant differences between the two treatment groups.
ACE  angiotensin-converting enzyme.
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relative standard curve method was used to calculate relative
gene expression.
Enzyme immunoassay. Protein levels of interleukin (IL)-8
(sensitivity of 10 pg/ml), macrophage inflammatory protein
(MIP)-1 (sensitivity of 10 pg/ml), and monocyte che-
moattractant protein (MCP)-1 (sensitivity of 5 pg/ml) were
determined by enzyme immunoassay (R&D Systems, Min-
neapolis, Minnesota).
Cell culture experiments. Cryopreserved PBMCs were
thawed as described elsewhere (9). The cells were cultured
with or without lipopolysaccharide from Escherichia coli/
O26:B6 (Sigma; final concentration of 10 ng/ml) in RPMI
1640 medium (Gibco), supplemented with 5% human AB
serum (Bio Whittaker, Whalkesville, Maryland) in 96-well
trays (106 cells/ml, 200 l/well; Costar by Corning, Cam-
bridge, Massachusetts). Supernatants were harvested after
20-h culturing and stored at 80°C.
Statistical analyses. The chemokine data were not nor-
mally distributed, and non-parametric tests were chosen for
the statistical analyses. The Mann-Whitney U test was used
for unpaired analyses, and the Wilcoxon matched-pair test
was used for paired analyses. P values 0.05 (two-sided)
were considered statistically significant. However, due to
multiple comparisons, particular attention should be di-
rected toward lower p values (i.e., 0.01).
RESULTS
As expected, both atorvastatin and simvastatin reduced total
cholesterol, low-density lipoprotein cholesterol, and triglyc-
eride levels in these patients during six months of therapy,
with a non-significant tendency toward a greater lipid-
lowering effect in the atorvastatin group (Table 2).
Chemokine and chemokine receptor gene expression in
PBMCs from CAD patients and healthy control subjects.
Before initiating statin therapy, the CAD patients had
markedly enhanced gene expression of MIP-1 (4.2-
fold), MIP-1 (5-fold), and IL-8 (2.3-fold), as com-
pared with healthy individuals (Fig. 1). In contrast, regu-
lated upon activation, normally T cell expressed and secreted
(RANTES) was equally expressed in these groups. The
signals obtained for the other chemokines (e.g., MCP-1)
were low in both CAD patients and controls, making them
unsuitable for quantitative analyses (Fig. 2).
Concomitant with the enhanced expression of MIP-1
and MIP-1, the gene expression of their corresponding
receptors (i.e., CCR1 and CCR5) was also increased in
PBMCs from CAD patients (Fig. 1). Moreover, CCR2
(i.e., the MCP-1 receptor) and CCR4 (i.e., the receptor for
thymus and activation-regulated chemokine and macrophage-
derived chemokine) were also up-regulated in CAD. In
contrast, CXCR1 and -2 (i.e., receptors for IL-8) and
CXCR4 (i.e., the receptor for stromal cell-derived factor-
1) were equally expressed in patients and controls (Fig. 1).
Effect of statin therapy on chemokine and chemokine
receptor expression. Several interesting effects were ob-
served on gene expression of chemokines and chemokine
receptors after six months of statin therapy. First, the
chemokines MIP-1, MIP-1, and IL-8 were markedly
reduced in both treatment groups, with particularly sup-
pressing effect in the atorvastatin group, in which the signals
of gene expression were nearly absent after therapy (Figs. 2
and 3). Secondly, gene expression of the chemokine recep-
tors CCR1 and CCR2 was also significantly inhibited by
the statins, with a similar effect in both treatment groups
(Fig. 3). In contrast, gene expression of CCR4 and CCR5,
which was markedly up-regulated in the CAD group (Fig.
1), as well as CXCR1, CXCR2, CXCR4, and RANTES,
which was equally expressed in CAD patients and controls,
was not affected by statin therapy (data not shown).
During statin therapy, we found no significant correlation
between changes in chemokines or chemokine receptors and
lipid parameters in either of the treatment groups. More-
over, most patients were taking aspirin throughout the study
period, and accordingly, the effects of statins were superim-
posed on any possible immunomodulating effect of aspirin.
Effect of in vivo statin therapy on MIP-1, IL-8, and
MCP-1 secretion from cultured, cryopreserved PBMCs.
The most prominent effect of statin therapy on gene
expression of chemokines was the marked reduction of
IL-8, MIP-1, and MIP-1. Although protein secretion
from cultured, cryopreserved cells is not completely equiv-
alent to protein levels in freshly isolated cells, we next
evaluated whether the down-regulating effect of statins was
also present at the protein level by analyzing the spontane-
ous and lipopolysaccharide-stimulated release of IL-8 and
MIP-1 from cryopreserved PBMCs isolated before and
after therapy. According to the important role of MCP-1 in
atherogenesis, this chemokine was also analyzed in PBMC
supernatants. As shown in Figure 4, atorvastatin therapy for





Baseline 6 Months Baseline 6 Months
Total cholesterol (mmol/l) 6.0  1.2 3.5  0.9* 6.0  1.1 4.0  0.6*
LDL cholesterol (mmol/l)† 4.1  1.3 1.8  0.6* 4.0  0.9 1.9  0.6*
HDL cholesterol (mmol/l) 1.1  0.4 1.2  0.4 1.1  0.2 1.3  0.3
Triglycerides (mmol/l) 2.0  1.1 1.2  0.4* 1.7  0.4 1.3  0.4*
*p  0.05 versus baseline. †Levels calculated from Friedewald’s formula. Data are presented as the mean value  SD.
HDL and LDL  high- and low-density lipoprotein, respectively.
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Figure 1. Gene expression of four chemokines (A), four CC chemokine receptors (CCR) (B), and three CXC chemokine receptors (CXCR) (C) in healthy
controls (CTR; n  15 in A and B and n  7 in C) and coronary artery disease (CAD) patients (CAD; n  30) before statin therapy. Horizontal lines
indicate median values. (A and B) Gene expression is assessed by ribonuclease protection assay, normalized to the house-keeping genes glyceraldehyde-
3-phosphate-dehydrogenase (GAPDH), and data are presented as percentage of GAPDH expression. (C) Gene expression is assessed by quantitative
reverse transcription-polymerase chain reaction and normalized to beta-actin expression. IL  interleukin; MIP  macrophage inflammatory protein;
mRNA  messenger ribonucleic acid; RANTES  regulated upon activation, normally T cell expressed and secreted.
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six months (n  13) significantly reduced the spontaneous
release of both IL-8 (Fig. 4A) and MIP-1 (Fig. 4B).
Although the messenger ribonucleic acid (mRNA) level of
MCP-1 in freshly isolated PBMCs was low (Fig. 2), these
cells spontaneously released a large amount of this chemo-
kine after culturing for 20 h. However, and in contrast to
the attenuating effect of statins on IL-8 and MIP-1, no
effect of atorvastatin was seen on MCP-1 secretion (Fig.
4C). In contrast to the inhibiting effect of statins on the
spontaneous release of chemokines, no effect was seen on
the lipopolysaccharide-stimulated release of IL-8, MIP-1,
or MCP-1 (data not shown). Similar patterns of chemokine
secretion were seen in four patients receiving simvastatin
(data not shown).
Effect of statin therapy on plasma levels of chemokines.
We also examined the effect of statin therapy on plasma
levels of chemokines. The plasma levels of MIP-1 and
IL-8 were low, just above (MIP-1) and below (IL-8) the
detection limits of the assays in both controls and CAD
patients both before and after therapy, thereby being un-
suitable for statistical analyses. Taking into consideration
the marked differences in gene expression of these chemo-
kines between CAD patients and controls, this may indicate
that measuring plasma levels of these chemokines, at least in
stable CAD patients, as in the present study, may have
substantial limitations. For MCP-1, there were no differ-
ences in plasma levels before and after statin therapy (137
7.1 vs. 132  5.9 pg/ml in the total study population).
DISCUSSION
Several studies in animal models suggest a crucial role of
chemokines in atherogenesis (11). Although caution is
needed when interpreting the results from multiple com-
parisons, the present study demonstrates markedly elevated
mRNA levels of several chemokines and chemokine recep-
tors in PBMCs from CAD patients, further supporting a
pathogenic role of increased chemokine activity in these
patients. Even more importantly, we found that statin
therapy inhibited the expression of some of these chemo-
kines (i.e., IL-8, MIP-1, and MIP-1) and chemokine
receptors (i.e., CCR1 and CCR2) at the cellular level in
PBMCs, as assessed at both the protein and mRNA levels.
We suggest that the down-regulating effect on the chemo-
kine network may contribute to the observed beneficial
effects of these drugs in CAD.
The involvement of chemokines and chemokine receptors
in the pathogenesis of atherosclerosis has been widely
investigated, particularly focusing on the effects of IL-8 and
MCP-1 and their corresponding receptors. Hence, en-
hanced expression of these chemokines has been found in
human atherosclerotic lesions, possibly mediating chemoat-
tractant and mitogenic effects on neutrophils, T cells, and
smooth muscle cells (12). Furthermore, macrophages with
enhanced expression of chemokine receptors (e.g., CXCR2)
have been reported in human and murine atheroma (11).
Also, knockout mice lacking IL-8 and MCP-1 or their
corresponding receptors (i.e., CXCR2 and CCR2) have
significantly reduced progression of atherosclerosis (11).
Accordingly, the down-regulatory effect of statins on the
expression of the MCP-1 receptor CCR2 in circulating
PBMCs in CAD patients could potentially impair athero-
genesis in these patients, at least partly by inhibiting the
recruitment of leukocytes into the vessel wall, even though
MCP-1 expression is unaffected. Moreover, if the down-
regulatory effects of statins on IL-8 expression also exist in
leukocytes within the atherosclerotic plaque, it may reduce
the inflammatory, matrix-degrading, and thrombotic effects
Figure 2. Representative ribonuclease protection assay of chemokines in
peripheral blood mononuclear cells from one control subject (CTR) and
one coronary artery disease (CAD) patient at baseline and after six months
of atorvastatin therapy. The left lane shows the positive control with all
chemokines represented on the hCK5 probe. Ltn  lymphotactin;
IP-10  interferon-gamma inducible protein-10; I-309  inducible-
309; MCP  monocyte chemoattractant protein; MIP  macrophage
inflammatory protein; RANTES  regulated upon activation, normally T
cell expressed and secreted. House-keeping (control) genes: rpL32 
ribosomal protein 32; GAPDH  glyceraldehyde-3-phosphate dehydro-
genase.
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of this chemokine, thereby promoting plaque stability and
reducing the susceptibility for developing plaque rupture
and acute coronary syndromes.
Enhanced MIP-1 and MIP-1 activation seems to
be involved in the pathogenesis of several inflammatory
disorders, and there are also some reports suggesting
their involvement in atherogenesis. Thus, not only
MCP-1 and IL-8 but also MIP-1, MIP-1, and
RANTES are expressed in atherosclerotic plaques (12).
Interestingly, MIP-1 and MIP-1 are expressed mainly
in T cells co-localized in macrophage-rich areas, suggesting
cross-talk between macrophages and T cells through che-
mokine signaling within the atherosclerotic lesion (5).
Moreover, Schecter et al. (13) recently reported that
MIP-1 increased tissue factor activity in vascular smooth
muscle cells, suggesting that this chemokine could mediate
both inflammatory and thrombotic responses within an
atherosclerotic plaque. Also, studies in CCR1 knockout
mice indicate the involvement of MIP-1 in the pathogen-
esis of allograft atherosclerosis (14). The increased expres-
sion of MIP-1 and MIP-1 and their corresponding
receptors CCR1 and CCR5 in PBMCs from CAD pa-
tients, as demonstrated in the present study, further sup-
ports a possible role of these mediators in atherogenesis.
Moreover, the inhibitory effect of statins on MIP-1 and its
corresponding receptor CCR1, as well as on MIP-1, could
be of importance for the anti-atherogenic effects of these
drugs. The pathogenic importance of these findings needs
to be further evaluated in forthcoming studies.
An important question is whether the pleiotropic effects
of statins are secondary to the reduction in cholesterol levels
or due to other mechanisms. Statins inhibit cholesterol
synthesis but also reduce the synthesis of non-steroidal
products in the mevalonate pathway. In vitro studies indi-
cate that suppression of these mediators may be responsible
for at least some of the anti-inflammatory effects seen with
Figure 3. Gene expression of macrophage inflammatory protein (MIP)-1 (A), MIP-1 (B), interleukin (IL)-8 (C), CC chemokine receptor (CCR)1 (D),
and CCR2 (E) from coronary artery disease patients at baseline and after six months of atorvastatin therapy (open circles; n  15) or simvastatin (solid
circles; n  15). Gene expression is normalized to the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data are presented as
the mean value  SEM. *p  0.05 and **p  0.01 versus baseline values. #p  0.01 comparing differences in changes between the two treatment groups.
mRNA  messenger ribonucleic acid.
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statins (15,16). Also, nuclear factor kappa-B, required for
transcription of several inflammatory cytokine and chemo-
kine genes, is down-regulated by statins, at least partly
independent of their cholesterol-lowering properties (17).
In the present study, we compared the immunomodulatory
effect of two extremities of statin therapy (i.e., high-dose
atorvastatin and conventional-dose simvastatin) in 30 CAD
patients. Although there was a tendency toward a more
prominent cholesterol-lowering effect of atorvastatin, this
difference did not reach statistical significance, probably
because of the relatively small sample sizes, compared with
studies focusing on the cholesterol-lowering effects of these
medications. However, although we could not demonstrate
any differences in the effect on cholesterol levels, atorvasta-
tin had a significantly more suppressive effect on MIP-1
and MIP-1 expression than did simvastatin, suggesting
that the effects of statin on chemokines are even more
potent than, and at least partly unrelated to, their lipid-
lowering properties. The lack of correlation between the
degree of cholesterol lowering and reduction in chemokine
and chemokine receptor expression further supports such a
notion. Alternatively, dose-dependent and -independent
differences in the immunomodulatory potencies of atorva-
statin and simvastatin may explain the more pronounced
inhibitory effect of atorvastatin on MIP-1 and MIP-1
levels. Additional studies are needed to elucidate these
issues. Nevertheless, despite some differences, both high-
dose atorvastatin and conventional-dose simvastatin had a
markedly down-regulatory effect on the chemokine net-
work, suggesting a class effect rather than a drug-specific
effect.
Although statins were found to have inhibitory effects on
the chemokine network, the present study also revealed
limitations of the anti-inflammatory effect of these medica-
tions. First, and in contrast to previous in vitro experiments
(8), the levels of MCP-1 were not affected in our study,
suggesting that this important mediator in atherogenesis is
not effectively suppressed during statin therapy in CAD
patients. Second, CCR5 and CXCR2 (18), which are
important for the arrest and migration of leukocytes
through the endothelium, remained unaltered during the
treatment period. Finally, although the gene expression of
MIP-1 and IL-8 from PBMCs was markedly down-
regulated, the effect on the protein secretion of IL-8 was
rather modest, and statins had no effect on the LPS-
stimulated release of these chemokines. These differences in
effect of statins on different chemokines may at least partly
reflect differences in the regulation of these chemokines
(19,20) and suggest a potential for other immunomodula-
tory treatment regimens in addition to statins in CAD and
other atherosclerotic disorders.
Increasing evidence suggests that the anti-inflammatory
effects of statins are not only curious side effects but also may
cause some of the beneficial clinical effects of statins in
CAD patients (4). Herein, we show markedly down-
regulatory effects of statins on the chemokine network in
CAD patients. We believe that these effects on chemokines
and chemokine receptors may contribute to the beneficial
effects of statins in CAD patients.
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Figure 4. Protein levels of macrophage inflammatory protein (MIP)-1 (A), interleukin (IL)-8 (B), and monocyte chemoattractant protein (MCP)-1 (C)
in supernatants from unstimulated, cryopreserved peripheral blood mononuclear cells (PBMCs) collected before (baseline) and after six months of
atorvastatin therapy in 13 coronary artery disease patients. The PBMCs were cultured for 20 h. Data are presented as the mean value  SD. *p  0.05
versus baseline.
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